Day: December 9, 2019

EINDHOVEN, The Netherlands, Dec. 09, 2019 (GLOBE NEWSWIRE) — NXP Semiconductors N.V. (NASDAQ: NXPI) today announced it will host an open house for the investment community at the 2020 Consumer Electronics Show. The event will enable buy-side and sell-side participants to engage with various NXP business leaders and experience product demonstrations to better understand the Company’s initiatives.Specific details:When: January 7, 2020, 8:30am to 9:30am PSTWhere: Consumer Electronics Show, Las Vegas NV, Central Plaza, location 18.During the open house, NXP will not facilitate private meetings with investors or analysts, nor provide an update to current business conditions as the Company will be in its quiet period ahead of fourth quarter earnings.Pre-registration is not required.About NXP SemiconductorsNXP Semiconductors N.V. (NASDAQ:...

HORSHAM, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL) (www.tollbrothers.com), the nation’s leading builder of luxury homes, today announced results for its fourth quarter and fiscal year ended October 31, 2019.FY 2019’s Fourth Quarter Financial Highlights (Compared to FY 2018’s Fourth Quarter):Net income and earnings per share were $202.3 million and $1.41 per share diluted, compared to net income of $311.0 million and $2.08 per share diluted in FY 2018’s fourth quarter.Pre-tax income decreased 31% to $272.6 million, compared to $396.5 million in FY 2018’s fourth quarter.Home sales revenues were $2.29 billion, down 7%; home building deliveries were 2,672, down 1%.Net signed contract value was $1.68 billion, up 12%; contract units were 2,031, up 18%.Backlog value at fourth-quarter end was $5.26 billion, down...

SAN MATEO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) — Franklin Resources, Inc. (Franklin Templeton) (NYSE: BEN) today reported preliminary month-end assets under management of $691.3 billion at November 30, 2019, compared to $693.1 billion at October 31, 2019. The decrease in assets under management was due to net outflows that offset market gains. Preliminary average assets under management for the quarter, through November 30, 2019, were $692.3 billion.Franklin Resources, Inc. [NYSE:BEN] is a global investment management organization operating as Franklin Templeton. Franklin Templeton’s goal is to deliver better outcomes by providing global and domestic investment management to retail, institutional and sovereign wealth clients in over 170 countries. Through specialized teams, the company has expertise across all asset classes,...

MITCHEL FIELD, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (NASDAQ: FEIM), will hold a conference call to discuss results for the second quarter of its fiscal year 2020, ended October 31, 2019, on Thursday, December 12, 2019, at 4:30 PM Eastern Time.This call is being webcast by Shareholder.com and can be accessed in the Investor Relations section of Frequency’s web site at www.freqelec.com.  Investors and analysts may also access the call by dialing 1-844-407-9500.  International callers may dial 862-298-0850.  Ask for the Frequency Electronics conference call.A telephone replay of the archived call will be available at 1-877-481-4010 (domestic), or 1-919-882-2331 (international), use pin 56885, for one week following the call. Subsequent to that, the call can be accessed via a link available on the company’s...

ROCKVILLE, Md., Dec. 09, 2019 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, is providing an update on the results from the first Phase III study (P301) of SPN-810, a novel treatment of Impulsive Aggression (IA) in patients with ADHD.In early November 2019, the Company reported topline results from the Phase III P301 trial in patients 6 to 11 years. The study was a randomized, double-blind, placebo controlled, multicenter, parallel group clinical trial in patients diagnosed with ADHD. Patients receiving SPN-810 36mg showed a median percent reduction of 58.6% in the average weekly frequency of impulsive aggression episodes from baseline that was not statistically significant (p=0.092)...

CAMP HILL, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) — Harsco Corporation (NYSE: HSC) announced today that its Environmental division has made a C$3M investment into Carbicrete, a Canadian technology company developing cement-free, carbon-negative concrete products made with steel slag for the construction industry.The innovation investment will give Harsco Environmental a Board seat in Carbicrete and has been made in conjunction with a C$2.1M grant from the Government of Canada’s Sustainability Development Technology Canada Foundation and applications to further government grant programs. Harsco’s investment will allow for the development of the innovative technology through a demonstration program with support from a commercial concrete block manufacturer as part of a development consortium.“This investment in innovation is aligned...

SAN RAMON, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO), will present at the J.P. Morgan Healthcare Conference in San Francisco, Calif., on January 14, 2020. Albert G. White III, President and Chief Executive Officer, will represent the Company in a presentation scheduled to begin at 4:30PM PT (7:30PM ET).A live audio webcast of the presentation will be available on the Investor Relations section of the Company’s website at http://investor.coopercos.com.About CooperCompaniesCooperCompanies (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact...

UNIONDALE, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (the “Company”) (NYSE: ABR) announced today that it plans to make a public offering of 6,000,000 shares of its common stock.  In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock.The Company intends to use the net proceeds from the offering to make investments relating to its business and for general corporate purposes. The Company also intends to use a portion of the net proceeds from this offering to purchase an aggregate of 600,000 shares, or 690,000 shares if the underwriters exercise in full their option to purchase additional shares, of the Company’s common stock from its Chief Executive Officer, Arbor Commercial Mortgage, LLC and/or an estate...

NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) — Pzena Investment Management, Inc. (NYSE: PZN) today reported its preliminary assets under management as of November 30, 2019.AUM for month-end November 2019, month-end October 2019, and month-end November 2018 are listed below:Pzena Investment Management, Inc.Assets Under Management1($ billions)1 Numbers may be subject to rounding.About PzenaPzena Investment Management, LLC, the firm’s operating company, is a value-oriented investment management firm.  Founded in 1995, Pzena Investment Management has built a diverse, global client base.  More firm and stock information is posted at www.pzena.com.Forward-Looking StatementsThis press release may contain, in addition to historical information, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,...

LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for itolizumab for the treatment of lupus nephritis. Equillium initiated the EQUALISE Phase 1b study of itolizumab in patients with lupus and lupus nephritis in September 2019.The FDA’s Fast Track program is designed to facilitate the development of new treatments for serious or life-threatening conditions for which there is a significant unmet medical need. Companies with investigational drugs that receive Fast Track designation benefit from more frequent meetings or communications with the FDA...